About GVB Biopharma
GVB Biopharma is a company based in United States founded in 2016 by Jack Feldman and Phillip Swindells was acquired by 22nd Century in May 2022. GVB Biopharma has raised $13.56 million across 6 funding rounds from investors including 22nd Century. GVB Biopharma offers products and services including CBD Isolate and White Label Products.
- Headquarter United States
- Founders Jack Feldman, Phillip Swindells
-
Sectors
Consumer
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Gvb Biopharma
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$13.56 M (USD)
in 6 rounds
-
Latest Funding Round
$1 M (USD), Series A
May 19, 2022
- Investors
-
Employee Count
Not available
-
Acquired by
22nd Century
(May 13, 2022)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of GVB Biopharma
GVB Biopharma offers a comprehensive portfolio of products and services, including CBD Isolate and White Label Products.
CBD isolate is produced and supplied as a hemp-based raw material for various applications.
White label products are provided for ingestibles and topicals, allowing customization for wholesale and retail use.
People of GVB Biopharma
Unlock access to complete
Unlock access to complete
Funding Insights of GVB Biopharma
GVB Biopharma has successfully raised a total of $13.56M across 6 strategic funding rounds. The most recent funding activity was a Series A round of $1 million completed in May 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in GVB Biopharma
GVB Biopharma has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include 22nd Century.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Manufacturer of nicotine products
|
Locked | Locked | Locked |
Investor details for GVB Biopharma
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by GVB Biopharma
Investment portfolio details for GVB Biopharma
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - GVB Biopharma
Detailed financials for GVB Biopharma
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Gvb Biopharma Comparisons
Peer comparison for GVB Biopharma
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of GVB Biopharma
Detailed competitors of GVB Biopharma
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Gvb Biopharma
Complete news archive for GVB Biopharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about GVB Biopharma
GVB Biopharma was founded in 2016 and raised its 1st funding round 4 years after it was founded.
GVB Biopharma is headquartered in United States.
Phillip Swindells is the current CEO of GVB Biopharma. They have also founded this company.
GVB Biopharma is a funded company, having raised a total of $13.56M across 6 funding rounds to date.
GVB Biopharma was established in 2016 in the United States, with operations centered on the cannabis sector. Cannabis extracts are manufactured and supplied, alongside white label solutions for product development. Services encompass extraction processes and formulation support for biopharma applications. Leadership is provided by co-founders Jack Feldman as President and Phillip Swindells as CEO, ensuring focus on regulatory-compliant production within the domestic market.
GVB Biopharma offers CBD Isolate and White Label Products.
GVB Biopharma has 1 investor. Key investors include 22nd Century.